

**Remarks**

**Claim Status**

Prior to the entry of this amendment, claims 1-12 were pending, claims 2 and 4-10 were withdrawn, and claims 1, 3, 11 and 12 were under examination. With the entry of this amendment, claims 1-10 will be pending, claims 2 and 4-10 will remain withdrawn, and claims 1 and 3 will be under examination

**Rejection of Claims 1, 3 and 12, Under 35 U.S.C. § 102(e)**

The Office rejected claims 1, 3 and 12, under 35 U.S.C. § 102(e), as allegedly anticipated by Webb. The Office countered Applicant's previous argument that Webb does not anticipate a claim to a method of treating diabetes with renin inhibitor monotherapy by pointing out that Applicant's claims were not limited to monotherapy. Applicant herein amends the claims to specify monotherapy and requests that the Office withdraw this rejection.

**Rejection of Claim 11, Under 35 U.S.C. § 103(a)**


The Office rejected claim 11, under 35 U.S.C. § 103(a), as allegedly unpatentable over Webb, in view of Bridon and Kirpichnikov. Applicant herein cancels claim 11, rendering the rejection moot.

**Conclusion**

For the foregoing reasons, Applicant urges that claims 1 and 3 are in condition for allowance and courteously requests that the Office withdraw all pending rejections. If there are any fees due in connection with the filing of this Amendment, please charge the fees to Deposit Account No. 19-0134.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-5442 (phone)  
(973) 781-8064 (fax)  
lisa.matovcik@novartis.com

Respectfully submitted,



Lisa Matovcik  
Attorney for Applicant  
Reg. No. 53,283

Date: 31 MAR 2010